MedPath
FDA Approval

Leukine

FDA-approved pharmaceutical product with comprehensive regulatory information, manufacturing details, and complete labeling documentation.

FDA Approval Summary

Company
Effective Date
August 31, 2023
Labeling Type
HUMAN PRESCRIPTION DRUG LABEL
Sargramostim(250 ug in 1 mL)

Manufacturing Establishments1

FDA-registered manufacturing facilities and establishments involved in the production, packaging, or distribution of this drug product.

Partner Therapeutics

Partner Therapeutics, Inc.

081059614

Products1

Detailed information about drug products covered under this FDA approval, including NDC codes, dosage forms, ingredients, and administration routes.

Leukine

Product Details

NDC Product Code
71837-5843
Application Number
BLA103362
Marketing Category
BLA (C73585)
Route of Administration
SUBCUTANEOUS, INTRAVENOUS
Effective Date
August 31, 2023
Code: 5TAA004E22Class: ACTIBQuantity: 250 ug in 1 mL
MANNITOLInactive
Code: 3OWL53L36AClass: IACTQuantity: 40 mg in 1 mL
WATERInactive
Code: 059QF0KO0RClass: IACT
HYDROCHLORIC ACIDInactive
Code: QTT17582CBClass: IACT
SUCROSEInactive
Code: C151H8M554Class: IACTQuantity: 10 mg in 1 mL
TROMETHAMINEInactive
Code: 023C2WHX2VClass: IACTQuantity: 1.2 mg in 1 mL
© Copyright 2025. All Rights Reserved by MedPath